Introducing SLT Into Practice

Selective laser trabeculoplasty puts glaucoma treatment back into physicians’ hands and takes the medication burden off patients.

By: Shivani S. Kamat, MD

Ophthalmology Management March 1, 2025 Vol 30, Issue March 2025 Page(s): 16-17

Clinical Report: Introducing SLT Into Practice

Overview

Selective laser trabeculoplasty (SLT) offers a promising alternative to traditional glaucoma treatments, significantly reducing the need for eye drops and improving patient compliance. The LiGHT trial demonstrated that SLT leads to better clinical outcomes and quality of life for patients with glaucoma.

Background

Glaucoma is a leading cause of blindness, affecting millions in the U.S. Traditional treatments often rely on patient adherence to topical medications, which can be challenging due to various factors. SLT represents a shift towards interventional approaches, allowing physicians to take a more active role in managing the disease.

Data Highlights

Outcome	SLT Group	Eye Drops Group
Required no additional eye drops	74.2%	N/A
Target IOP maintained at visits	93%	N/A
Lower rates of progression	Yes	No

Key Findings

SLT reduces the dependence on glaucoma drops, improving patient compliance.
74.2% of patients treated with SLT required no additional eye drops to maintain target IOP.
93% of visits for SLT patients maintained target IOP.
SLT is associated with lower rates of disease progression and need for surgery.
SLT enhances patient quality of life by minimizing medication side effects and costs.

Clinical Implications

Incorporating SLT as a first-line treatment can streamline patient management and reduce the burden of medication adherence. Physicians should consider dedicating time in their practice for SLT procedures to enhance patient outcomes and clinic efficiency.

Conclusion

SLT represents a significant advancement in glaucoma management, offering effective treatment with improved patient adherence and quality of life. Its integration into clinical practice can transform the approach to managing this chronic disease.

PentaVision

Ophthalmology Management